



1/2

Compound I monotherapy significantly inhibits vascular pathology  
(chronic rejection atherosclerosis)  
in murine MHCII mismatched cardiac transplant model




FIG. 1

2/2

Compound 1 significantly inhibits chronic rejection vasculopathy in  
fully mismatched (MHC I and MHC II disparate)  
Mouse cardiac allografts\*




FIG. 2